A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid arthritis.

Abstract

The adverse effects associated with this apheresis based treatment proved to be manageable and of short duration and resolved without sequelae. The results suggest that extracorporeal protein A therapy may have a role in the management of refractory RA, and encouraged the initiation of a larger, blinded, controlled clinical trial.